IL6R and rheumatoid arthritis: Two recently published studies attempted a thorough evaluation and data synthesis of current evidence relevant to implementing JAK inhibitors or bDMARDs in RA cases to determine their pooled efficacy and safety to placebo, yet the IL-6R inhibitor sarilumab was not incorporated in these analyses [9].